Levomilnacipran: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Levomilnacipran. Educational only — not medical advice.
Labeled uses
FETZIMA® is indicated for the treatment of major depressive disorder (MDD) in adults [see Clinical Studies ( 14 )]. Limitation of Use: FETZIMA is not approved for the management of fibromyalgia. The efficacy and safety of FETZIMA for the management of fibromyalgia have not been established.
Source: FDA labeling via NIH DailyMed (set f371258d…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.